Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence

By sjmartinez • January 25, 2025

Krishnan S, Srivastava PK, Attaluri J, Nayeri R, Chatterjee D, Patel J, Nsair A, Budoff M, Nayeri A. Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence. J Cardiovasc Dev Dis. 2025 Jan 7;12(1):19. doi: 10.3390/jcdd12010019. PMID: 39852297; PMCID: PMC11766028.

Tags: Cardiology/Epi, GIP GLP-1 receptor agonist, Harbor UCLA, Hematology/Oncology, Metabolic syndrome, Obesity, Publications, semaglutide, tirzepatide, Veterans Administration, weight loss

Author Correction: Viscoelastic synthetic antigen-presenting cells for augmenting the potency of cancer therapies

Liu Z, Li YR, Yang Y, Zhu Y, Yuan W, Hoffman T, Wu Y, Zhu E, Zarubova J, Shen J, Nan H, Yeh KW, Hasani-Sadrabadi[...]

The Impact of Intravascular Ultrasound Use on 1-Year Outcomes After Infrapopliteal Endovascular Intervention

Snyder DJ, Zilinyi RS, Kido T, Saleem D, Dreyfus I, Bruce S, Wadden E, Girvin Z, Finn MT, Kirtane AJ, Maehara A, Sethi SS, Parikh[...]

Visit-to-Visit Variability in Lipid Levels and Risk of Incident Heart Failure in Adults With Type 2 Diabetes

Kaze AD, Ndumele CE, Martin SS, Santhanam P, Yeneneh BT, Farouk M, Tung R, Fonarow GC, Echouffo-Tcheugui JB. Visit-to-Visit Variability in Lipid Levels and Risk[...]